1. Introduction

Reproductive genetic screening is an important area of biotechnology and medical law because it involves the identification of genetic disorders, inherited diseases and chromosomal abnormalities that may affect prospective parents, embryos or unborn children.

In Morocco, reproductive genetic screening raises important legal and ethical questions concerning:

The right of prospective parents to receive genetic information.

Informed and voluntary consent to genetic testing.

Prevention of serious hereditary diseases.

Preimplantation genetic diagnosis (PGD).

Prenatal genetic screening and diagnosis.

Protection of embryos and human dignity.

Confidentiality of genetic and reproductive information.

Prevention of discrimination based on genetic characteristics.

Regulation of fertility clinics and genetic laboratories.

Morocco's legal framework is particularly significant because Law No. 47-14 of 2019 on Medically Assisted Procreation expressly regulates preimplantation genetic diagnosis in certain circumstances. The country's personal-data protection legislation also recognises genetic information as sensitive personal data.

An important distinction must be made: Morocco has statutory provisions governing particular reproductive genetic procedures, but this does not mean that every form of prenatal or preconception genetic screening has a comprehensive, separate statutory framework.

2. Legal Framework Governing Reproductive Genetic Screening in Morocco

A. Law No. 47-14 of 2019 on Medically Assisted Procreation

The principal legislation governing reproductive genetic screening in Morocco is Law No. 47-14, promulgated by Dahir No. 1-19-50 of 11 March 2019.

The legislation recognises medically assisted procreation as a means of addressing medically diagnosed infertility and preventing the transmission of serious diseases to unborn children.

Its Articles 19–21 are particularly important.

Article 19: Preimplantation genetic diagnosis

Article 19 establishes that preimplantation genetic diagnosis (PGD) may be undertaken to identify incurable diseases included in the applicable regulatory list, with the objective of protecting the future child.

Its main requirements are:

The purpose must be prevention of specified serious genetic diseases.

The prospective parents must provide written consent.

A qualified practitioner must establish the relevant hereditary risk.

The procedure must satisfy the statutory medical conditions.

Authorisation must be obtained from the competent administration following consultation with the advisory commission.

The provision also requires that only healthy embryos be transferred under the regulated procedure.

This article is important because it prevents unrestricted genetic selection and establishes a medically justified basis for embryo screening.

Ma Loi+1

Article 20: Therapeutic intervention involving embryos

Article 20 provides a special exception allowing PGD for the purpose of enabling therapeutic treatment of an embryo.

The provision requires specific circumstances:

The couple must previously have had a child affected by a qualifying incurable genetic disease.

That disease must have resulted in the child's death during the early years of life.

Treatment of the embryo must decisively improve the future child's prospects of survival.

The treatment must not compromise the physical integrity of the embryo.

Both spouses must provide written consent.

Administrative authorisation and consultation with the advisory commission are required.

The provision therefore distinguishes therapeutic genetic intervention from genetic selection for non-medical preferences.

Ma Loi+1

Article 21: Professional qualifications and laboratory authorisation

Article 21 establishes professional and institutional safeguards.

It requires:

Prescription by an authorised practitioner.

Consultation with one or more genetic specialists.

Performance by a separately authorised genetic specialist.

Use of a specially authorised cytogenetic and molecular genetics laboratory.

Compliance with prescribed technical standards.

The requirement that the doctor performing the diagnosis be different from the doctor who provided the initial opinion promotes professional independence and reduces conflicts of interest.

This provision is central to preventing inaccurate genetic screening and unethical embryo selection.

Ma Loi+1

B. Law No. 09-08 on Personal Data Protection

Morocco's Law No. 09-08 of 18 February 2009 provides another essential layer of protection.

Genetic information is expressly recognised as sensitive personal data under Article 1.

This is particularly relevant because reproductive screening may reveal:

Hereditary disease risks.

Carrier status.

Chromosomal abnormalities.

Familial genetic characteristics.

Reproductive health information.

Genetic information concerning biological relatives.

Important provisions:

A particularly important distinction concerns Article 21. Although genetic information is sensitive, Article 21 and the applicable exceptions must be read together with Article 22, which provides a declaration-based regime for certain health-data processing carried out for medical prevention, diagnosis and treatment by professionals bound by confidentiality.

Consequently, genetic screening laboratories must identify the correct regulatory procedure rather than assume that every medical genetic test is automatically exempt from CNDP oversight.

BDJ+1

C. Constitution of Morocco, 2011

Article 24 of the Moroccan Constitution guarantees the right to protection of private life.

This constitutional protection has significant implications for reproductive genetic screening.

It supports the protection of:

Genetic privacy.

Confidential reproductive medical records.

Family medical histories.

Confidentiality of prenatal test results.

Protection against unauthorised disclosure of genetic information.

Article 25 also guarantees freedom of scientific and technical research.

However, scientific freedom does not provide unlimited permission to conduct genetic experiments or reproductive screening without regard to human dignity, privacy and statutory restrictions.

CNDP+1

D. Law No. 28-13 on Biomedical Research

Morocco's Law No. 28-13 of 2015 concerns the protection of persons participating in biomedical research.

It is relevant where reproductive genetic screening is conducted as part of a research project rather than ordinary clinical diagnosis.

For example:

Experimental prenatal genetic screening.

Research into hereditary reproductive disorders.

Validation of new embryo-screening technologies.

Research involving human biological samples.

Clinical evaluation of innovative genetic diagnostic methods.

Such research must comply with the applicable legal safeguards, including participant protection, consent and ethical review.

It is important not to confuse ordinary clinical genetic diagnosis with experimental research: the applicable legal requirements may differ. The Ministry of Health lists Laws No. 28-13 and No. 47-14 among its medical-practice legislation.

sante.gov.ma

3. Ethical Principles Governing Reproductive Genetic Screening

A. Informed consent

Informed consent is one of the most important ethical principles.

Prospective parents must understand the purpose, limitations and potential consequences of genetic screening.

Consent should address:

The genetic condition being investigated.

The accuracy and limitations of the test.

The possibility of uncertain results.

The possibility of false-positive or false-negative findings.

The implications for biological relatives.

The possible emotional consequences.

The handling and retention of genetic information.

For PGD under Article 19 and Article 20 of Law No. 47-14, written consent from both spouses is expressly required.

Consent should not be obtained through coercion, misleading advertising or pressure from fertility clinics.

B. Genetic counselling

Genetic counselling is essential before and after reproductive genetic screening.

A genetic counsellor or qualified specialist should explain the medical significance of the results in language that prospective parents can understand.

For example, a couple carrying a hereditary condition may have different reproductive options depending on the inheritance pattern and severity of the disease.

Counselling should explain these options without imposing a particular reproductive decision.

C. Prevention of eugenic practices

An important ethical concern is the possibility that genetic screening may be used to select embryos based on non-medical preferences.

Examples include selection based on:

Preferred physical characteristics.

Intelligence-related traits.

Cosmetic characteristics.

Social preferences.

Non-medical sex selection.

Morocco's Article 19 provides a restricted medical purpose for PGD: the identification of specified incurable diseases.

Therefore, the provision should not be interpreted as a general authorisation for designing children according to parental preferences.

D. Protection of embryonic dignity

Genetic screening creates difficult questions about the moral and legal status of embryos.

The selection of embryos based on genetic characteristics raises concerns about:

The treatment of embryos carrying genetic abnormalities.

The storage of screened embryos.

Decisions concerning embryos that are not selected for transfer.

The use of embryos for research.

The boundaries of therapeutic genetic intervention.

Article 20 is particularly relevant because it establishes conditions for therapeutic intervention involving an embryo.

E. Prevention of genetic discrimination

Genetic information must not become a basis for unjustified discrimination.

For instance, an individual identified as a carrier of a hereditary disease should not automatically be treated as medically unfit for marriage, employment or ordinary social participation.

The sensitivity of genetic information under Law No. 09-08 supports strict controls on its collection, disclosure and use.

F. Confidentiality and reproductive privacy

Reproductive genetic screening can disclose information not only about the person tested but also about their family members.

For example, a woman undergoing genetic screening may discover that she carries a hereditary mutation also present in her siblings.

Clinics must therefore establish confidentiality procedures covering:

Medical records.

Laboratory reports.

Genetic databases.

Electronic reproductive records.

Communication with external laboratories.

Transfer of information to foreign medical institutions.

Article 23 and Article 24 of Law No. 09-08 are particularly important in this context.

4. Judicial Decisions and Case Laws

An important research limitation must be recognised: I have not identified a reported Moroccan appellate or Supreme Court judgment specifically deciding the legality or ethics of reproductive genetic screening or PGD under Law No. 47-14.

The following international decisions are therefore comparative authorities. They are useful for interpreting ethical questions and developing legal arguments, but European Court of Human Rights judgments are not binding precedents in Morocco.

Case 1: Costa and Pavan v. Italy (2012)

Important comparative authority

Court: European Court of Human Rights.

Application No.: 54270/10.

Judgment date: 28 August 2012.

Legal issue: Access to preimplantation genetic diagnosis.

Facts:

The applicants were healthy carriers of cystic fibrosis. Their first child was born with the disease.

During a subsequent pregnancy, prenatal testing established that the foetus was affected by cystic fibrosis. The couple decided to terminate the pregnancy on medical grounds.

They subsequently sought access to assisted reproduction and PGD to avoid transmitting the genetic disease.

Italian legislation prevented them from accessing the procedure.

Judgment:

The European Court of Human Rights found a violation of Article 8 of the European Convention on Human Rights, which protects private and family life.

The Court considered the inconsistency between prohibiting embryo screening and permitting termination of a pregnancy affected by the same genetic disease.

It found that the interference with the couple's private and family life was disproportionate.

HUDOC+1

Relevance to Morocco:

This judgment provides an important comparative argument for allowing medically justified genetic screening.

Morocco has addressed part of this issue through Article 19 of Law No. 47-14, which expressly permits PGD under specified medical circumstances.

The case also demonstrates the importance of maintaining consistency between reproductive medical policies and the protection of prospective parents' reproductive autonomy.

Case 2: R.R. v. Poland (2011)

Court: European Court of Human Rights.

Application No.: 27617/04.

Judgment date: 26 May 2011.

Legal issue: Access to prenatal genetic diagnosis and reproductive healthcare.

Facts:

A pregnant woman was informed that her foetus might have a serious genetic abnormality.

She sought prenatal genetic testing to establish the condition of the foetus.

However, medical institutions delayed access to the necessary tests and she experienced difficulties obtaining proper medical information and counselling.

Judgment:

The Court found violations of Articles 3 and 8 of the European Convention on Human Rights.

It emphasised the importance of effective access to prenatal diagnostic services, appropriate medical information and respect for reproductive privacy.

The case demonstrated that medical professionals must not frustrate a patient's lawful access to diagnostic procedures through unjustified delays or inadequate information.

Chamber Judgment+1

Relevance to Morocco:

This judgment is relevant to Moroccan reproductive healthcare in three respects:

Genetic screening should be accessible through properly regulated medical services.

Patients should receive accurate and timely information about diagnostic procedures.

Medical professionals should respect patient autonomy and professional obligations.

It also supports the importance of genetic counselling before and after prenatal testing.

Case 3: Evans v. United Kingdom (2007)

Court: European Court of Human Rights, Grand Chamber.

Application No.: 6339/05.

Judgment date: 10 April 2007.

Legal issue: Reproductive autonomy and control over stored embryos.

Facts:

The applicant underwent fertility treatment and had embryos created using her eggs and her partner's sperm.

Following the breakdown of their relationship, her former partner withdrew his consent to the embryos being used.

The dispute concerned whether the embryos could be implanted without his continued consent.

Judgment:

The Court examined the competing reproductive rights of both parties and the importance of consent in assisted reproduction.

It did not find a violation of Article 8 in the circumstances of the case.

Relevance to Morocco:

The decision provides useful comparative guidance concerning:

Consent in assisted reproductive procedures.

Reproductive autonomy.

Control over stored embryos.

The rights and interests of both prospective parents.

The legal importance of continuing consent.

It is particularly relevant when genetic screening is undertaken as part of IVF and embryo storage.

HUDOC

Case 4: S.H. and Others v. Austria (2011)

Court: European Court of Human Rights, Grand Chamber.

Application No.: 57813/00.

Judgment date: 3 November 2011.

Legal issue: State regulation of assisted reproductive technology.

Facts:

The applicants challenged Austrian restrictions on certain forms of assisted reproduction, particularly the use of donor sperm and donor eggs.

They argued that the restrictions interfered with their rights to private and family life.

Judgment:

The Grand Chamber considered the sensitive ethical and social questions involved in reproductive technology.

It recognised that states have a degree of discretion when regulating medically assisted reproduction, particularly where there is no European consensus on the ethical issues.

The Court did not find a violation of Article 8 in the circumstances.

Relevance to Morocco:

The judgment demonstrates that reproductive genetic screening can legitimately be subject to statutory controls.

It also illustrates the need to balance:

Medical innovation.

Parental autonomy.

Protection of embryos.

Public health.

Ethical and social considerations.

HUDOC+1

Comparative case-law analysis

These judgments offer comparative guidance rather than direct interpretations of Moroccan legislation.

5. Regulatory Responsibilities of Moroccan Institutions

Several institutional actors are relevant to reproductive genetic screening.

1. Ministry of Health and Social Protection

Its responsibilities include the administration and implementation of applicable healthcare legislation, including the regulatory framework for assisted reproduction.

2. Competent administrative authority under Law No. 47-14

It is responsible for the authorisations required by the legislation, including the regulated PGD process.

3. Advisory Commission

The commission participates in the statutory review of PGD applications and provides the required consultation before administrative authorisation.

4. National Commission for the Control of Personal Data Protection (CNDP)

The CNDP oversees compliance with Law No. 09-08, including the protection of sensitive genetic and reproductive information.

5. Authorised medical practitioners and genetic laboratories

These professionals and institutions must comply with the applicable qualifications, authorisation, technical and confidentiality requirements.

6. Major Legal and Ethical Challenges in Morocco

A. Limited scope of statutory PGD

Article 19 does not create unrestricted access to all forms of reproductive genetic testing.

Its scope is restricted to specified incurable diseases and qualifying medical circumstances.

A significant challenge is ensuring that the applicable disease list and regulatory requirements remain medically current.

B. Regulation of prenatal genetic screening

Prenatal screening and preimplantation genetic diagnosis are different procedures.

PGD examines embryos before transfer, whereas prenatal screening investigates the possibility of genetic or chromosomal conditions during pregnancy.

Morocco's Law No. 47-14 expressly addresses PGD. Its provisions should not automatically be interpreted as a comprehensive statutory code for every prenatal screening technique.

More detailed guidance on prenatal screening, counselling and diagnostic consent would help improve legal certainty.

C. Unequal access to genetic services

Advanced genetic screening can be expensive and may be concentrated in specialised urban medical facilities.

This raises questions concerning equal access to reproductive healthcare, particularly for economically disadvantaged families and people living in rural areas.

D. Genetic information and family privacy

Genetic test results can reveal information about biological relatives who have not themselves consented to testing.

Morocco's data protection framework provides an important foundation, but practical safeguards are necessary when genetic information is shared with laboratories, researchers or foreign institutions.

E. Commercialisation of genetic screening

Private clinics may have financial incentives to promote expensive screening packages.

Ethical regulation should prevent:

Misleading claims about test accuracy.

Advertising unsupported genetic predictions.

Unnecessary medical procedures.

Pressure to undertake embryo screening.

Commercial promises of genetically superior children.

F. Artificial intelligence in reproductive genetics

AI-assisted embryo analysis and predictive genetic models create additional legal concerns.

These include:

Algorithmic errors.

Biased risk predictions.

Lack of clinical transparency.

Inaccurate embryo classification.

Unauthorised secondary use of genetic information.

Morocco's existing laws on assisted reproduction and personal-data protection provide relevant legal safeguards, although they do not constitute a comprehensive AI-specific framework for reproductive genetics.

7. Recommendations for Strengthening Moroccan Law

The following reforms could improve the regulation of reproductive genetic screening in Morocco.

1. Specific prenatal screening legislation: Establish clearer rules for prenatal genetic screening, diagnostic testing and clinical counselling.

2. Mandatory genetic counselling: Require appropriate pre-test and post-test counselling for individuals undergoing significant reproductive genetic investigations.

3. Updated genetic disease lists: Regularly review the diseases eligible for PGD under Article 19 of Law No. 47-14.

4. Laboratory accreditation: Strengthen inspection, quality assurance and professional accountability for genetic testing laboratories.

5. Genetic privacy protection: Establish clear standards for storage, disclosure, international transfer and destruction of reproductive genetic information.

6. Prohibition of non-medical genetic selection: Clarify restrictions on genetic selection for cosmetic, social or other non-medical preferences.

7. Protection against discrimination: Strengthen safeguards against misuse of genetic information by employers, insurers and other private organisations.

8. AI accountability: Introduce standards for validation, transparency and professional supervision of AI-assisted reproductive genetic screening.

9. Accessible genetic services: Improve access to genetic counselling and diagnostic services outside major urban centres.

8. Conclusion

The regulation of reproductive genetic screening ethics in Morocco involves balancing reproductive autonomy, medical innovation, human dignity, genetic privacy and the protection of future children.

Law No. 47-14 of 2019 establishes an important statutory framework through Articles 19, 20 and 21. These provisions regulate preimplantation genetic diagnosis, require written consent from both spouses, establish medical eligibility requirements and impose professional and laboratory authorisation safeguards.

Law No. 09-08 further protects genetic and reproductive information by recognising genetic data as sensitive personal data and establishing requirements for consent, confidentiality and information security.

The comparative judgments in Costa and Pavan v. Italy, R.R. v. Poland, Evans v. United Kingdom and S.H. and Others v. Austria provide useful judicial guidance on reproductive autonomy, informed consent, prenatal diagnosis and the regulation of assisted reproductive technologies.

Ultimately, Morocco needs a coherent approach that permits medically justified genetic screening while preventing genetic discrimination, non-medical embryo selection, privacy violations and irresponsible commercial exploitation.

The central principle should be that reproductive genetic screening must serve legitimate medical purposes, respect informed parental consent and protect human dignity.

9. Important Legal References and Research Sources

Primary research materials:

Full text of Moroccan Law No. 47-14.

Official Moroccan legal database – Law No. 09-08.

Moroccan Ministry of Health – Medical practice legislation.

CNDP – Personal data protection legislation.

Costa and Pavan v. Italy – ECHR judgment.

R.R. v. Poland – ECHR judgment.

Academic note: This analysis distinguishes binding Moroccan statutory provisions from comparative international case law. It does not identify a directly applicable reported Moroccan court judgment on reproductive genetic screening ethics. The current implementing regulations and administrative disease lists should also be checked before relying on the analysis in litigation or clinical compliance.